Flawed ivermectin preprint highlights challenges of COVID drug studies.
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“It has been reported that the data for ~79 participants were duplicates, some deaths were recorded on dates before the trial had started, and instances of plagiarism were identified in the text [12].”
From Ivermectin for COVID-19: Addressing Potential Bias and Medical Fraud (2022) · cites this paper as [12]
Citations
Cites
1 retracted
WITHDRAWN: Efficacy and Safety of Ivermectin for Treatment and prophylaxis of COVID-19 Pandemic
Elgazzar, A., Eltaweel, A., Youssef, S. A., Hany, B., Hafez, M., & Moussa, H. (2020) · doi:10.21203/rs.3.rs-100956/v3 · Cited by 17
RetractedThe FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro.
Caly, L., Druce, J. D., Catton, M. G., Jans, D. A., & Wagstaff, K. M. (2020) · Antiviral Research · doi:10.1016/j.antiviral.2020.104787 · Cited by 2,179
Bryant, A., Lawrie, T. A., Dowswell, T., Fordham, E. J., Mitchell, S., Hill, S. R., & Tham, T. C. (2021) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001402 · Cited by 264
Ivermectin for preventing and treating COVID-19
Popp, M., Stegemann, M., Metzendorf, M.-I., Gould, S., Kranke, P., Meybohm, P., Skoetz, N., & Weibel, S. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd015017.pub2 · Cited by 167
Cited by
A living WHO guideline on drugs for covid-19 (2020-2023)
Agarwal, A., Hunt, B. J., Stegemann, M., Rochwerg, B., Lamontagne, F., Siemieniuk, R. A., Agoritsas, T., Askie, L., Lytvyn, L., Leo, Y.-S., et al. (2020) · BMJ · doi:10.1136/bmj.m3379 · Cited by 1,041
Effect of Early Treatment with Ivermectin among Patients with Covid-19
Reis, G., Silva, E. A. S. M., Silva, D. C. M., Thabane, L., Milagres, A. C., Ferreira, T. S., dos Santos, C. V. Q., Campos, V. H. S., Nogueira, A. M. R., de Almeida, A. P. F. G., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2115869 · Cited by 224
Čalušić, M., Marčec, R., Luksa, L., Jurkovic, I., Kovač, N., Mihaljević, S., & Likić, R. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15126 · Cited by 87
COVID‐19 in Latin America and the Caribbean: Two years of the pandemic
Schwalb, A., Armyra, E., Méndez‐Aranda, M., & Ugarte‐Gil, C. (2022) · Journal of Internal Medicine · doi:10.1111/joim.13499 · Cited by 86
Johnson-Arbor, K. K. (2022) · Clinical Toxicology · doi:10.1080/15563650.2022.2043338 · Cited by 82
“However, the interpretation of these reports is limited by multiple factors including the inclusion of preprint (non-peer reviewed) data, differences in treatment regimens between study and control groups, and allegations of plagiarism and data fabrication that resulted in study retraction [42].”
Background
Metadata
- Authors
- Reardon, S.
- Corresponding author
- Reardon, Sara
- Venue
- Nature
- Published
- 2021-08-02
- Volume
- 596
- Issue
- 7871
- Pages
- 173-174
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W3187849685
- Cited by
- 83
- References
- 4
- Citations by year
- 2026: 2 · 2025: 5 · 2024: 7 · 2023: 31 · 2022: 25 · 2021: 12
- Type
- other
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Library and Information Sciences › Academic Publishing and Open Access
- Keywords
- ivermectin, COVID-19 treatment, antiparasitic drugs, drug repurposing, antiviral therapy
- MeSH terms
- Preprints as Topic, COVID-19, COVID-19 Drug Treatment, Antiparasitic Agents, Clinical Trials as Topic, Humans, Ivermectin, Research Personnel, Retraction of Publication as Topic, World Health Organization, Plagiarism, Scientific Misconduct, Sample Size, Pandemics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Flawed ivermectin preprint highlights challenges of COVID drug studies. https://app.cochat.ai/papers/10.1038/d41586-021-02081-w
- The paper
- Reardon, S. (2021). Flawed ivermectin preprint highlights challenges of COVID drug studies. Nature. https://doi.org/10.1038/d41586-021-02081-w
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.